Alevin Therapeutics Ltd
Groundbreaking new therapies for diseases with unmet clinical need
DATE FIRST INVESTED
We aim for therapeutic applications in diseases with high unmet clinical need: fibrosis, in particular idiopathic pulmonary fibrosis (IPF), liver and kidney disease, and cancer.
Our team has created a platform of novel small molecules targeting specific pathways within complex integrin biology. We aim to develop our preclinical and discovery-stage assets towards clinical application, to offer new treatments and relief for millions of patients affected by life-limiting conditions for which no effective therapy currently exists.